Butylated Hydroxytoluene (CID 31404) - BioAssay Data Summary for Compound
.
BioActivity Outcomes:
Active(40)
 
 
Inactive(839)
 
 
Inconclusive(32)
 
 
Unspecified(169)
 
 
Top Targets:
7TM GPCR Srx(19)
 
 
NR LBD PPAR(16)
 
 
 
NR LBD TR(12)
 
 
 
Bcl-2 like(11)
 
 
alkPPc(10)
 
 
BioAssay Types:
Screening(434)
 
 
 
Confirmatory(388)
 
 
 
 
 
Literature(200)
 
 
 
 
 
BioActivity Types:
Potency(303)
 
 
 
 
 
IC50(77)
 
 
 
 
 
EC50(12)
 
 
 
 
 
Ki(2)
 
 
 
SAR
Target summary
Data download

Chemical Probe    Active    Inactive    Inconclusive    Unspecified   

Total Bioassays: 971    Data Row: 1080   Total Pages: 22   Display: Page     
Sort: [Click the result table header to sort]
#SubstanceActivityBioAssayTargetLinks
OutcomeTypeValue [μM]
1
[SID103199241]
IC50 0.04Antioxidant activity assessed as DPPH free radical scavenging activity after 30 mins by TLC autographic assay [AID403737, Type: Literature]
View
2
[SID103199241]
Ki 0.63Inhibition of human erythrocyte CA2 esterase activity using 4-nitrophenyl acetate substrate [AID416126, Type: Literature]Carbonic anhydrase 2 [gi:115456]
View
3
[SID103199241]
IC50 0.9Compound was tested for [Ca2+] overload inhibitory activity in the veratridine-induced [Ca2+] overload model of rat cardiac myocytes. [AID196205, Type: Literature]
View
4
[SID103199241]
IC50 1.7Tested for inhibition of ferrous salt/ascorbate induced lipidic peroxidation of membrane lipid of rat hepatocytes [AID248526, Type: Literature]
View
5
[SID103199241]
IC50 1.7Antioxidant activity assessed as inhibition of TBARS production in ferrous salt/ascorbate-induced lipid peroxidation in Wistar rat liver microsomal membrane [AID264513, Type: Literature]
View
6
[SID103199241]
IC50 3Antioxidant activity assessed as inhibition of copper-induced human LDL oxidation [AID360576, Type: other]
View
7
[SID103199241]
IC50 3.18Induction of DNA fragmentation in human HL60 cells after 16 hrs [AID282840, Type: Literature]
View
8
[SID103199241]
IC50 3.2Inhibition of NADH-induced lipid peroxidation in rat brain microsome [AID312786, Type: Literature]
View
9
[SID103199241]
IC50 3.25Ability to inhibit [Fe2+] inducedlipid peroxidation (LPO) in rat brain microsomes [AID195850, Type: Literature]
View
10
[SID103199241]
IC50 3.25Inhibition of ferrous induced lipid peroxidation in rat brain microsomes [AID262310, Type: Literature]
View
11
[SID103199241]
IC50 4.03Compound was tested for its inhibitory concentration against formation of lipid peroxides in rat brain homogenates by thiobarbituric acid reactive substances (TBARS) assay according to the method of Stocks. [AID195714, Type: Literature]
View
12
[SID103199241]
IC50 4.03Inhibition of lipid peroxidation in Sprague-Dawley rat brain after 30 mins by TBARS assay [AID314540, Type: Literature]
View
13
[SID103199241]
IC50 5.9Compound was tested for 50% Inhibition of lipid peroxidation in rat brain homogenate [AID195548, Type: Literature]
View
14
[SID103199241]
IC50 5.9Compound was tested for its inhibitory activity against lipid peroxidation in rat brain homogenates. [AID179221, Type: Literature]
View
15
[SID103199241]
EC50 6Ability to protect cerebellar granule cells (CGC) from iodoacetate (IAA)-induced toxicity [AID196215, Type: other]
View
16
[SID103199241]
IC50 6.2Inhibition of Fe2+-induced lipid peroxidation in rat brain homogenate [AID312787, Type: Literature]
View
17
[SID103199241]
IC50 10.23Antioxidant activity assessed as residual ABTS+ radical scavenging activity after 30 mins by spectrophotometric analysis [AID619938, Type: Literature]
View
18
[SID103199241]
IC50 11.5Antioxidant activity assessed as residual DPPH radical scavenging activity after 30 mins by spectrophotometric analysis [AID619937, Type: Literature]
View
19
[SID11532869]
Potency 12.9953qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in absence of CPT [AID686978, Type: confirmatory]TDP1 protein [Homo sapiens] [gi:79154014]
View
20
[SID11532869]
Potency 12.9953qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in absence of CPT [AID686978, Type: confirmatory]TDP1 protein [Homo sapiens] [gi:79154014]
View
21
[SID11532869]
Potency 12.9953qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in absence of CPT [AID686978, Type: confirmatory]TDP1 protein [Homo sapiens] [gi:79154014]
View
22
[SID103199241]
IC50 14.5Antiplatelet activity against rabbit platelet assessed as inhibition of platelet-activating factor-induced platelet aggregation at 20 uM preincubated 3 mins before PAF challenge by turbidimetric method relative to control [AID333976, Type: Literature]
View
23
[SID26753102]
Potency 17.7828qHTS assay for small molecule agonists of retinoid X receptor alpha signaling [AID588544, Type: confirmatory]retinoid X nuclear receptor alpha [Homo sapiens] [gi:325495497]
View
24
[SID26753102]
Potency 17.7828qHTS assay for small molecule agonists of retinoid X receptor alpha signaling [AID588544, Type: confirmatory]retinoid X nuclear receptor alpha [Homo sapiens] [gi:325495497]
View
25
[SID26753102]
Potency 17.7828qHTS assay for small molecule agonists of retinoid X receptor alpha signaling [AID588544, Type: confirmatory]retinoid X nuclear receptor alpha [Homo sapiens] [gi:325495497]
View
26
[SID103199241]
IC50 19Antioxidant activity assessed as DPPH free radical scavenging activity [AID333732, Type: Literature]
View
27
[SID103199241]
IC50 19.7Compound was tested in vitro for [Ca2+] antagonistic activity in K+-depolarized isolated rat aorta [AID195193, Type: Literature]
View
28
[SID103199241]
IC50 28.45Antioxidant activity assessed as superoxide radical scavenging activity after 40 mins by Zhishen's method [AID619939, Type: Literature]
View
29
[SID103199241]
IC50 30Compound tested to inhibit (LPO) lipid peroxidation was determined in rat brain microsomes [AID181671, Type: Literature]
View
30
[SID103199241]
IC50 30Antioxidant activity assessed as DPPH radical scavenging activity by TLC autographic assay [AID402313, Type: Literature]
View
31
[SID103199241]
IC50 32.5Antioxidant potency of compound was assessed for their ability to inhibit [Fe2+] induced lipid peroxidation in rat brain microsomes [AID181537, Type: Literature]
View
32
[SID103199241]
IC50 36.98Antioxidant activity assessed as ABTS radical scavenging activity after 3 mins by spectrophotometric analysis [AID626497, Type: Literature]
View
33
[SID48413347]
 DSSTox (CPDBAS) Carcinogenic Potency Database Summary Mouse Bioassay Results [AID1199, Type: other]
View
34
[SID103199241]
 Antioxidant activity assessed as hydrogen peroxide scavenging activity at 60 ug/ml by spectrophotometry [AID353029, Type: Literature]
View
35
[SID103199241]
 Antioxidant activity assessed as DPPH radical scavenging activity by spectrophotometric assay [AID360933, Type: Literature]
View
36
[SID48415183]
 DSSTox (EPAFHM) EPA Fathead Minnow Acute Toxicity [AID1188, Type: other]
View
37
[SID48413347]
 DSSTox (CPDBAS) Carcinogenic Potency Database Summary MultiCellCall Results [AID1205, Type: other]
View
38
[SID48413347]
 DSSTox (CPDBAS) Carcinogenic Potency Database Summary SingleCellCall Results [AID1189, Type: other]
View
39
[SID103199241]
 Inhibition of human CYP1A2 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using ethoxyresorufin as substrate after 30 mins [AID678712, Type: Literature]Cytochrome P450 1A2 [gi:117144]
View
40
[SID103199241]
 Inhibition of human CYP1A2 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using ethoxyresorufin as substrate after 30 mins [AID678712, Type: Literature]Cytochrome P450 1A2 [gi:117144]
View
41
[SID103199241]
 Inhibition of human CYP1A2 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using ethoxyresorufin as substrate after 30 mins [AID678712, Type: Literature]Cytochrome P450 1A2 [gi:117144]
View
42
[SID103199241]
 Inhibition of human CYP2C19 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 3-butyryl-7-methoxycoumarin as substrate after 30 mins [AID678714, Type: Literature]Cytochrome P450 2C19 [gi:60416369]
View
43
[SID103199241]
 Inhibition of human CYP2C19 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 3-butyryl-7-methoxycoumarin as substrate after 30 mins [AID678714, Type: Literature]Cytochrome P450 2C19 [gi:60416369]
View
44
[SID103199241]
 Inhibition of human CYP2C9 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 7-methoxy-4-trifluoromethylcoumarin-3-acetic acid as substrate after 30 mins [AID678713, Type: Literature]Cytochrome P450 2C9 [gi:6686268]
View
45
[SID103199241]
 Inhibition of human CYP2C9 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 7-methoxy-4-trifluoromethylcoumarin-3-acetic acid as substrate after 30 mins [AID678713, Type: Literature]Cytochrome P450 2C9 [gi:6686268]
View
46
[SID103199241]
 Inhibition of human CYP2C9 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 7-methoxy-4-trifluoromethylcoumarin-3-acetic acid as substrate after 30 mins [AID678713, Type: Literature]Cytochrome P450 2C9 [gi:6686268]
View
47
[SID103199241]
 Inhibition of human CYP2D6 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 4-methylaminoethyl-7-methoxycoumarin as substrate after 30 mins [AID678715, Type: Literature]Cytochrome P450 2D6 [gi:84028191]
View
48
[SID103199241]
 Inhibition of human CYP2D6 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 4-methylaminoethyl-7-methoxycoumarin as substrate after 30 mins [AID678715, Type: Literature]Cytochrome P450 2D6 [gi:84028191]
View
49
[SID103199241]
 Inhibition of human CYP3A4 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using diethoxyfluorescein as substrate after 30 mins [AID678716, Type: Literature]Cytochrome P450 3A4 [gi:116241312]
View
50
[SID103199241]
 Inhibition of human CYP3A4 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using diethoxyfluorescein as substrate after 30 mins [AID678716, Type: Literature]Cytochrome P450 3A4 [gi:116241312]
View